Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Fosphenytoin sodium
Drug ID BADD_D00971
Description Fosphenytoin is a water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures. It works by slowing down impulses in the brain that cause seizures. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repetitive firing of action potentials.
Indications and Usage For the control of generalized convulsive status epilepticus and prevention and treatment of seizures occurring during neurosurgery. It can also be substituted, short-term, for oral phenytoin.
Marketing Status Prescription; Discontinued
ATC Code N03AB05
DrugBank ID DB01320
KEGG ID D02096
MeSH ID C043114
PubChem ID 56338
TTD Drug ID D0J5YC
NDC Product Code 0641-6137; 29902-0023; 52952-005; 65162-998; 65162-999; 0143-9788; 0069-5474; 64679-729; 63323-403; 0143-9782; 67457-517; 0069-6001; 14998-0018; 0069-5471; 0641-6136; 64679-730; 72375-0005; 82019-0002; 67457-516; 62756-874; 62331-027
Synonyms fosphenytoin | 3-(hydroxymethyl)phenytoin phosphate ester | ACC 9653 | ACC-9653 | Prodilantin | fosphenytoin sodium | fosphenytoin, disodium salt | 3-(hydroxymethyl)phenytoin disodium phosphate | HMPDP | Cerebyx
Chemical Information
Molecular Formula C16H13N2Na2O6P
CAS Registry Number 92134-98-0
SMILES C1=CC=C(C=C1)C2(C(=O)N(C(=O)N2)COP(=O)([O-])[O-])C3=CC=CC=C3.[Na+].[Na+]
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Urethral pain20.02.02.014--Not Available
Urinary incontinence20.02.02.010; 17.05.01.008--
Urinary retention20.02.02.011--
Urticaria10.01.06.001; 23.04.02.001--
Vaginal infection11.01.10.002; 21.14.02.002--
Vaginal inflammation21.14.02.001--
Vasodilatation24.03.02.003; 23.06.05.006--Not Available
Ventricular extrasystoles02.03.04.007--Not Available
Vertigo17.02.12.002; 04.04.01.003--
Visual field defect06.02.07.003; 17.17.01.001--Not Available
Vomiting07.01.07.003--
Vulvovaginal candidiasis21.14.02.003; 11.03.03.005--Not Available
Brain oedema17.07.02.003; 12.01.10.010--
Musculoskeletal discomfort15.03.04.001--Not Available
Injection site swelling08.02.03.017; 12.07.03.018--Not Available
Affect lability19.04.01.001--Not Available
Congestive cardiomyopathy02.04.01.003--Not Available
Rectal tenesmus15.05.03.011; 07.03.03.001--Not Available
Paraesthesia oral17.02.06.008; 07.05.03.003--Not Available
Muscle relaxant therapy25.16.01.001--Not Available
Urine output increased13.13.03.002--Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Ill-defined disorder08.01.03.049--Not Available
Urinary tract obstruction20.08.01.004--
Psychotic disorder19.03.01.002--
Increased bronchial secretion22.02.04.007--Not Available
Vulvovaginal mycotic infection21.14.02.004; 11.03.05.004--Not Available
Skin mass23.07.04.014--Not Available
Anorectal discomfort07.03.03.003--Not Available
Depersonalisation/derealisation disorder19.14.01.004--Not Available
The 7th Page    First    Pre   7    Total 7 Pages